Small Molecule NIK Inhibitors for NF-kB Pathway
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for autoimmune diseases, inflammatory disorders, and cancers lack effective NIK inhibitors that can specifically target and inhibit NF-κB-inducing kinase (NIK) pathways, leading to inadequate management of associated conditions.
Innovation Solution
Development of specific compounds, such as those described in Formula I, which act as NIK inhibitors, capable of inhibiting the NF-κB-inducing kinase pathways to treat various diseases by forming pharmaceutical compositions that can be used to prevent or treat conditions mediated by NIK.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for autoimmune diseases and inflammatory disorders are used, then existing therapeutic options are available, but they lack effective NIK inhibition capability leading to inadequate disease management
Solution Approach 1:
The patent develops small molecule compounds with specific molecular structures (Formula I) that change the pharmacological parameters of NIK inhibition. These compounds possess optimized molecular weight, lipophilicity, and binding affinity parameters to effectively inhibit NIK kinase activity and downstream NF-κB pathways, thereby resolving the inadequacy of existing treatments
Solution Approach 2:
The invention segments the broad immune response pathway into specific NIK-dependent signaling cascades. By designing compounds that selectively target NIK kinase activity rather than broadly suppressing immune function, the treatment achieves precise pathway inhibition while maintaining other immune functions, thus improving disease management effectiveness
2Object-generated harmful factors
If NIK inhibition is implemented to treat autoimmune diseases and cancers, then therapeutic benefits are achieved, but development of specific and effective NIK inhibitors is currently lacking
Solution Approach 1:
The patent employs small molecule compounds as intermediary substances that mediate inhibition between NIK kinase and downstream inflammatory pathways. These compounds serve as chemical mediators that bind to NIK's ATP binding site, preventing phosphorylation of downstream targets like IKKα and p100, thereby blocking inflammatory molecule production without requiring direct genetic manipulation
Solution Approach 2:
The invention replaces complex biological systems (such as biologics or genetic therapies) with small molecule chemical compounds that can be synthesized and manufactured more easily. These small molecules offer advantages in stability, oral bioavailability, and manufacturing scalability compared to biologics, thus improving ease of manufacture while achieving NIK inhibition
Data Source
AI summary
This invention relates to compounds of Formula I that inhibit NIK and pharmaceutical compositions comprising such compounds and methods of using the same. These compounds and pharmaceutical compositions are useful for preventing or treating diseases such as cancer (such as B-cell malignancies including leukemias, lymphomas and myeloma), inflammatory disorders, autoimmune disorders, immunodermatologic disorders such as palmoplantar pustulosis and hidradenitis suppurativa, and metabolic disorders such as obesity and diabetes.